Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 0.97 | 0.57% | 0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| Historical ALNA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Resistance | Bearish | 0.57% | |
| NR7 | Range Contraction | 0.57% | |
| Stochastic Reached Oversold | Weakness | 0.57% | |
| Oversold Stochastic | Weakness | 0.57% | |
| 20 DMA Resistance | Bearish | 1.04% | |
| Fell Below 50 DMA | Bearish | 1.04% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Resistance | 1 day ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Up 5% | 1 day ago |
| Rose Above 20 DMA | 1 day ago |
| Up 3% | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 08/03/2021
Allena Pharmaceuticals, Inc. Description
Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Organ Systems Gastrointestinal Kidney Diseases Orphan Disease Orphan Diseases Crystals Hyperoxaluria Chronic Management
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.77 |
| 52 Week Low | 0.75 |
| Average Volume | 3,450,474 |
| 200-Day Moving Average | 1.30 |
| 50-Day Moving Average | 0.96 |
| 20-Day Moving Average | 1.00 |
| 10-Day Moving Average | 1.02 |
| Average True Range | 0.06 |
| ADX | 16.14 |
| +DI | 21.43 |
| -DI | 17.78 |
| Chandelier Exit (Long, 3 ATRs) | 0.93 |
| Chandelier Exit (Short, 3 ATRs) | 0.99 |
| Upper Bollinger Bands | 1.11 |
| Lower Bollinger Band | 0.88 |
| Percent B (%b) | 0.39 |
| BandWidth | 22.38 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.0067 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.06 | ||||
| Resistance 3 (R3) | 1.07 | 1.04 | 1.04 | ||
| Resistance 2 (R2) | 1.04 | 1.02 | 1.04 | 1.04 | |
| Resistance 1 (R1) | 1.01 | 1.01 | 1.00 | 1.00 | 1.03 |
| Pivot Point | 0.98 | 0.98 | 0.98 | 0.98 | 0.98 |
| Support 1 (S1) | 0.95 | 0.96 | 0.94 | 0.94 | 0.91 |
| Support 2 (S2) | 0.92 | 0.95 | 0.92 | 0.90 | |
| Support 3 (S3) | 0.89 | 0.92 | 0.90 | ||
| Support 4 (S4) | 0.88 |
